Progress in Immunotherapy for Squamous Non-small Cell Lung Cancer
10.3779/j.issn.1009-3419.2016.10.09
- VernacularTitle:肺鳞癌的免疫治疗进展
- Author:
WANG SHOUZHENG
1
;
LI JUNLING
Author Information
1. 国家癌症中心/中国医学科学院北京协和医学院肿瘤医院
- Keywords:
Lung neoplasms;
Immunotherapy;
Checkpoint inhibitors;
Tumour vaccines
- From:
Chinese Journal of Lung Cancer
2016;19(10):682-686
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, squamous non-small cell lung cancer (NSCLC) didn’t progress much in chemotherapy or target therapy. However, immunotherapy has made breakthroughs in treating squamous NSCLC. Immunotherapy includes two main broad classes of immune checkpoint inhibitors and therapeutic vaccines. Immune checkpoint inhibitors, including anti cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) and anti programmed death receptor 1 (PD-1) antibodies, have been tested in the phase II/III clinical trials and have demonstrated promising outcomes. Immunotherapy will become an im-portant treatment for squamous NSCLC.
